Adicet Bio, Inc. Additional Paid in Capital, Common Stock
Adicet Bio, Inc. (ACET) had Additional Paid in Capital, Common Stock of $776.54 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital, Common Stock $776.54M.
- 2026-03-31: Additional Paid in Capital, Common Stock $775.04M.
- 2025-12-31: Additional Paid in Capital, Common Stock $773.79M.
- 2025-09-30: Additional Paid in Capital, Common Stock $693.26M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $776.54M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $775.04M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $773.79M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $693.26M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $690.73M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $687.55M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $684.48M 10-K · filed 2026-03-12 | $684.48M 10-K · filed 2025-03-06 |
| 2024-09-30 | $680.57M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $673.79M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $667.58M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $550.94M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $545.96M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $540.46M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $535.21M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $530.45M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $525.89M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $479.51M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $474.79M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $471.45M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $369.73M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $366.84M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $363.90M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $216.13M 10-K · filed 2022-03-15 | |
| 2020-09-30 | $214.21M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $237.51M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $236.75M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $9.26M 10-K · filed 2021-03-12 | $235.78M 10-K · filed 2020-03-12 |
| 2019-09-30 | $234.89M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $227.56M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $222.88M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $175.63M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |